Get the Stockscreener App
6.79
3.43%
0.225
Valneva Se Adr stock is traded at $6.79, with a volume of 12,728.
It is up +3.43% in the last 24 hours and down -2.68% over the past month.
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.
See More
Previous Close:
$6.565
Open:
$6.73
24h Volume:
12,728
Relative Volume:
0.16
Market Cap:
$589.19M
Revenue:
$163.13M
Net Income/Loss:
$-34.75M
P/E Ratio:
-13.18
EPS:
-0.5152
Net Cash Flow:
$-231.66M
1W Performance:
+7.61%
1M Performance:
-2.68%
6M Performance:
+20.82%
1Y Performance:
-12.39%
1-Day Range:
$6.68
$6.91
1-Week Range:
$5.9943
$7.30
52-Week Range:
$3.62
$9.50
Valneva Se Adr Stock (VALN) Company Profile
Compare VALN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VALN
Valneva Se Adr
|
6.79 | 589.19M | 163.13M | -34.75M | -231.66M | -0.5152 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Valneva Se Adr Stock (VALN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-03-22 | Initiated | H.C. Wainwright | Buy |
Valneva Se Adr Stock (VALN) Latest News
Valneva fait le point sur la recommandation de l'ACIP pour les voyageurs américains concernant son vaccin IXCHIQ® contre le chikungunya - GlobeNewswire Inc.
Valneva shares leap on Brazilian approval of chikungunya vaccine By Investing.com - Investing.com South Africa
Valneva shares leap on Brazilian approval of chikungunya vaccine - Investing.com Australia
VALN Doses First Infant With Shigella Vaccine in Mid-Stage Study - MSN
VALN Doses First Infant With Shigella Vaccine In Mid-Stage Study - Barchart.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SEVALN - PR Newswire
The Schall Law Probes Valneva Over Vaccine Safety Concerns - Lawyer Monthly
VALN Investors Have Opportunity to Join Valneva SE Fraud Investigation with the Schall Law Firm - Business Wire
Valneva SE earnings missed by $0.32, revenue fell short of estimates - Investing.com India
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Valneva SE (VALN) and Encourages Stockholders to Learn More About the Investigation - markets.businessinsider.com
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Valneva SE (VALN) And Encourages Shareholders to Reach Out - Markets Insider
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Valneva SE (VALN) and Encourages Shareholders to Learn More About the Investigation - Markets Insider
Valneva SE (VALN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - Markets Insider
Bronstein, Gewirtz & Grossman, LLC Encourages Valneva SE (VALN) Shareholders to Inquire about Securities Investigation - Markets Insider
Bronstein, Gewirtz & Grossman, LLC Is Investigating Valneva SE (VALN) And Encourages Investors to Connect - Markets Insider
Bronstein, Gewirtz & Grossman, LLC Encourages Valneva SE (VALN) Stockholders to Inquire about Securities Investigation - Markets Insider
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Valneva SE (VALN) and Encourages Investors to Learn More About the Investigation - Markets Insider
Valneva SE (VALN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - Markets Insider
Bronstein, Gewirtz & Grossman, LLC Is Investigating Valneva SE (VALN) And Encourages Stockholders to Connect - markets.businessinsider.com
Valneva SE (VALN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - Markets Insider
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Valneva SE (VALN) and Encourages Stockholders to Learn More About the Investigation. - Markets Insider
ATTENTION VALN SHAREHOLDERS: Investors who lost money on Valneva SE are urged to contact Levi & Korsinsky about an ongoing investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Valneva SE (VALN) Investors to Inquire about Securities Investigation - Markets Insider
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Valneva SE (VALN) And Encourages Investors to Reach Out - Markets Insider
H.C. Wainwright cuts Valneva stock target to $17, maintains Buy By Investing.com - Investing.com South Africa
H.C. Wainwright cuts Valneva stock target to $17, maintains Buy - Investing.com
Déclaration d'actions et de droits de vote de la société Valneva SE - GlobeNewswire Inc.
Valneva stock holds $18 target on UK vaccine nod By Investing.com - Investing.com India
Favorable VLA1553-321 Phase 3 Study Results Boost VALN Stock - Yahoo Finance
VALNEVA - GlobeNewswire Inc.
Chikungunya Vaccine Label Extension Call Likely to Support VALN Stock - Yahoo Finance
Valneva SE earnings missed by $0.02, revenue fell short of estimates - Investing.com
Valneva SE (VALN) Q3 2024 Earnings Report Preview: What to Look For - Yahoo Finance
H.C. Wainwright maintains Buy rating on Valneva SE stock, lowers price target By Investing.com - Investing.com South Africa
H.C. Wainwright maintains Buy rating on Valneva SE stock, lowers price target - Investing.com
Valneva shares hold strong with buy rating on Lyme vaccine data - Investing.com
Favorable VLA15 Phase 2 Study Results Might Boost VALN Stock - Yahoo Finance
Valneva (VALN) Stock Down 53% in the Past Year: Here's Why - Nasdaq
Valneva (VALN) Stock Down 66% in the Past 6 Months: Here's Why - Nasdaq
Valneva (VALN) Down as EU Considers Ending COVID-Vaccine Deal - Yahoo Finance
Valneva Stock Is Jumping on European Vaccine Supply Deal - Barron's
Valneva (VALN) Reports Positive Data From COVID Vaccine Study - Nasdaq
Valneva Stock Plunges as U.K. Drops Covid-19 Vaccine Deal - Barron's
Shareholder StructureHome - Home - Valneva
Stock Price - Valneva
Valneva Se Adr Stock (VALN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):